Revolution Medicines reported updated phase I/II results for daraxonrasib in previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) at AACR, adding first-line monotherapy and combination data to its earlier RAS inhibitor Phase 3 signal. The company is positioning daraxonrasib as a broader RAS(ON) multi-selective approach that aims to extend survival in a disease with limited options. Separate coverage of Revolution’s meeting disclosures highlighted tumor shrinkage and six-month progression control rates in both the monotherapy and daraxonrasib-plus-chemotherapy groups. Analysts have linked the AACR updates to expectations for its ongoing Phase 3 RASolute 303 study, which is set up to test the drug across multiple RAS contexts. Market participants continue to treat Revolution as a potential consolidation target, although reported deal rumors have cooled as the company pushes deeper into front-line efficacy.